ICUDDR-Logo click for home.

< Back to All Resources

FDA warns about the risk of xylazine exposure in humans

The United States Food and Drug Administration (FDA) is communicating to health care professionals about serious risks associated with xylazine exposure in humans and considerations for management. 

Acute and repeated xylazine exposure may be associated with clinically significant harms such as delaying the diagnosis and management of polysubstance overdose; developing severe, necrotic skin ulcerations; and interfering with the successful treatment of opioid use disorder (OUD).


Adobe PDF PDF of letter

Related Topics